Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the ADHD symptom response of adults with ADHD treated with OROS MPH to those treated with placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
• Treatments: Methylphenidate

Criteria

Inclusion Criteria:

• Adults

• ADHD diagnosis (any type: Combined, Predominantly Inattentive, or Predominantly Hyperactive-Impulsive)

• Patients with an Adult ADHD Investigator Symptom Rating Scale (AISRS) score greater than 24 at screening/baseline

• Ability to read and understand English

Exclusion Criteria:

• Any significant history of cardiovascular disease or cardiovascular disease detectable via ECG

• History of diagnosis of substance or alcohol dependence or admission/hospitalization for rehabilitation for dependence

• Current neurologic or psychiatric diagnosis that would make patient inappropriate for participation

• Anxiety assessments of moderate or severe

• Depression assessments of moderate or severe

• History or current suicidal thoughts or attempts

• Known allergies, hypersensitivity, or intolerance to OROS MPH